Dimerix Stock

Dimerix Current Assets

The Current Assets of Dimerix (DXB.AX) as of Sep 3, 2026 is 72.18 M AUD. In the previous year, Current Assets was 31.92 M AUD — a change of 126.15% (higher).

Current Assets

72.18 MAUD

YoY

126.15%

Last updated:

Current Assets of Dimerix is 2026 72.18 M AUD. Current Assets of Dimerix was 2025 31.92 M AUD. It decreases by 126.15% higher compared to the previous year.

The Dimerix Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2018
7.26 M AUD
Jan 1, 2019
4.94 M AUD
Jan 1, 2020
10.39 M AUD
Jan 1, 2021
5.41 M AUD
Jan 1, 2022
10.10 M AUD
Jan 1, 2023
8.20 M AUD
Jan 1, 2024
31.92 M AUD
Jan 1, 2025
72.18 M AUD
The Dimerix Current Assets history
YEARCurrent AssetsYoY
72.18 MAUD+126.15%
31.92 MAUD+289.33%
8.20 MAUD-18.86%
10.10 MAUD+86.70%
5.41 MAUD-47.91%
10.39 MAUD+110.36%
4.94 MAUD-32.02%
7.26 MAUD+153.24%
2.87 MAUD+13.69%
2.52 MAUD-14.87%
2.96 MAUD+144.95%
1.21 MAUD-31.25%
1.76 MAUD+47.90%
1.19 MAUD-19.05%
1.47 MAUD+25.64%
1.17 MAUD+207.89%
380,000.00AUD-36.67%
600,000.00AUD-17.81%
730,000.00AUD-37.07%
1.16 MAUD-51.87%
2.41 MAUD+73.38%
1.39 MAUD+124.19%
620,000.00AUD-46.09%
1.15 MAUD-24.34%
1.52 MAUD—
Access this data via the Eulerpool API
Get Free API Key

Dimerix Stock analysis

What does Dimerix do? Dimerix Ltd is an Australian biotechnology company specializing in the development of innovative therapies for various medical needs. Their business model is based on identifying new targets for drug development, often through collaborations with other biotech or pharmaceutical companies. Dimerix focuses on cancer therapy, utilizing their innovative platform technology to identify and test a variety of drug candidates. They also have a pipeline of medications for kidney and lung diseases, as well as inflammation and pain. Dimerix actively seeks partnerships with other companies and research institutions to bring innovative therapies to market. One of their key products, DMX-200, is currently in phase II clinical trials for the treatment of kidney diseases and has shown promising results. Overall, Dimerix is well-positioned to continue bringing successful therapies to market in the future. Dimerix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Dimerix stock

Current Assets of Dimerix is 72.18 M AUD in 2026.

Current Assets of Dimerix changed from 31.92 M AUD to 72.18 M AUD, representing a 126.15% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Current Assets Dimerix since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's Dimerix historically and in real time.

Access this data via the Eulerpool API
Get Free API Key

Balance Sheet — Dimerix

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Dimerix